Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II study of EDIT-101 for the treatment of Leber Congenital Amaurosis type 10 (LCA10)

Trial Profile

A Phase I/II study of EDIT-101 for the treatment of Leber Congenital Amaurosis type 10 (LCA10)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs EDIT-101 (Primary)
  • Indications Leber congenital amaurosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan; Editas Medicine
  • Most Recent Events

    • 07 Jan 2019 According to an Editas Medicine media release, plane of this study will be discussed at 37th Annual J.P. Morgan Healthcare Conference.
    • 07 Jan 2019 According to an Editas Medicine media release, company plans to initiate patient screening mid-year and begin patient dosing in the second half of 2019, enrolling 10-20 patients in the U.S. and Europe.
    • 30 Nov 2018 According to an Editas Medicine media release,The U.S. Food and Drug Administration (FDA) has accepted Investigational New Drug (IND) application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top